SCHEMBL13060381

SCHEMBL13060381

CNC(=O)C1CCCCCCCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
EPHX1 P07099 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NAAA Q02083 1/20 0.47
TSHR P16473 2/20 0.47
MAPK1 P28482 1/20 0.47
HSD11B1 P28845 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
PTPN1 P18031 1/20 0.45
HPGD P15428 1/20 0.45
CHRNB2 P17787 2/20 0.45
CHRNA4 P43681 2/20 0.45
CHRNA7 P36544 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1679607 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL413228 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18938465 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18934846 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL6917808 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL24618011 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL1678569 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL18935496 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
SCHEMBL21212072 1.00 HDAC8 (0.61) HDAC8HDAC6EPHX1CES2CES1
Hydrochloric Acid SCHEMBL7274485 0.97 HDAC8 (0.58) HDAC8HDAC6EPHX1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-03-16 US disclosed
US-8334320-B2 Methods for chelation therapy UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-12-18 US disclosed
US-20100310460-A1 COMPOSITIONS AND METHODS FOR CHELATION THERAPY LIU GANG 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310460-A1 COMPOSITIONS AND METHODS FOR CHELATION THERAPY SOST, SOD3, HIF1AN HDAC8 1001/4885HDAC6 583/4885EPHX1 629/4885
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP HDAC8 3581/4885HDAC6 2274/4885EPHX1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.